REFERENCES
1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
3. Gallo M, Muscogiuri G, Felicetti F, et al. Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metabolism 2018;78:141-54.
4. Milluzzo A, Vigneri P, Martorana F, Vigneri R, Sciacca L. Type 2 diabetes and cancer: problems and suggestions for best patient management. Explor Med 2020;1:184-204.
5. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85.
6. Vella V, Milluzzo A, Scalisi NM, Vigneri P, Sciacca L. Insulin receptor isoforms in cancer. Int J Mol Sci 2018;19:3615.
7. Cignarelli A, Genchi VA, Caruso I, et al. Diabetes and cancer: pathophysiological fundamentals of a 'dangerous affair'. Diabetes Res Clin Pract 2018;143:378-88.
8. Sciacca L, Scalisi NM, Cassarino MF, et al. Different effects of the insulin receptor isoforms on 32D cell growth and differentiation. J Diabetes Endocrinol Metab Disord 2017:1-9.
9. Pinheiro LC, Soroka O, Kern LM, Leonard JP, Safford MM. Diabetes care management patterns before and after a cancer diagnosis: a SEER-Medicare matched cohort study. Cancer 2020;126:1727-35.
10. Milluzzo A, Tumminia A, Vella V, et al. Short-term adverse effects of anticancer drugs in patients with type 2 diabetes. J Chemother 2019;31:150-9.
11. ElSayed NA, Aleppo G, Aroda VR, et al. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. Diabetes Care 2023;46:S203-15.
12. Takao T, Suka M, Yanagisawa H, Matsuyama Y, Iwamoto Y. Predictive ability of visit-to-visit variability in HbA1c and systolic blood pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes. Diabetes Res Clin Pract 2017;128:15-23.
13. Jampol LM, Glassman AR, Sun J. Evaluation and care of patients with diabetic retinopathy. N Engl J Med 2020;382:1629-37.
14. Tumminia A, Milluzzo A, Carrubba N, Vinciguerra F, Baratta R, Frittitta L. Excessive generalized and visceral adiposity is associated with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2023:Online ahead of print.
15. Milluzzo A, Barchitta M, Maugeri A, Agodi A, Sciacca L. Body mass index is related to short term retinal worsening in type 2 diabetes patients treated with anticancer drugs. Minerva Endocrinol 2022:Online ahead of print.
16. Milluzzo A, Maugeri A, Barchitta M, Sciacca L, Agodi A. Epigenetic mechanisms in type 2 diabetes retinopathy: a systematic review. Int J Mol Sci 2021;22:10502.
17. Milluzzo A, Barchitta M, Maugeri A, et al. Do nutrients and nutraceuticals play a role in diabetic retinopathy? Nutrients 2022;14:4430.
18. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277-86.
19. Liu CY, Francis JH, Brodie SE, et al. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies. Retina 2014;34:1261-80.
20. Gianni L, Panzini I, Li S, et al. International Breast Cancer Study Group (IBCSG). Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer 2006;106:505-13.
22. Moussa K, Kim J, Miller JB. Retinal exudates and hemorrhages in a survivor of breast cancer. JAMA Ophthalmol 2019;137:218-9.
23. Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity. BMJ Case Rep 2016;2016:bcr2015213431.
24. Bradley MC, Zhou Y, Freedman AN, et al. Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer. Cancer Causes Control 2018;29:785-91.
25. Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007;100:1060-5.
26. Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24.
27. Hershey DS, Bryant AL, Olausson J, Davis ED, Brady VJ, Hammer M. Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature. Oncol Nurs Forum 2014;41:E343-54.
28. Matsuyama K, Ando A, Wada M, Ogata N, Nishimura T. Case of ischemic retinopathy induced by chemotherapy with paclitaxel and carboplatin. Acta Ophthalmol 2008;86:0-0.
29. Elhusseiny AM, Smiddy WE. Carboplatin- and/or paclitaxel-induced ischemic retinopathy. Can J Ophthalmol 2020;55:e95-8.
30. Bassi E, Loizzi V, Furino C, et al. Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol 2017;7:285-7.
31. Chelala E, Arej N, Antoun J, et al. Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients. Chemotherapy 2017;62:199-204.
32. Hilliard LM, Berkow RL, Watterson J, Ballard EA, Balzer GK, Moertel CL. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol 1997;28:310-3.
33. Kwan AS, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am J Ophthalmol 2006;141:196-7.
34. Tran THC, Desauw C, Rose C. Gemcitabine-induced retinopathy in a diabetic patient. Acta Ophthalmol 2009;87:114-5.
35. Higashide T, Murotani E, Sugiyama K. Cystoid macular edema associated with oral antineoplastic agent s-1 in a patient with diabetic retinopathy. Case Rep Ophthalmol 2012;3:91-5.
36. Méndez-Martínez S, Calvo P, Ruiz-Moreno O, et al. Ocular adverse events associated with mek inhibitors. Retina 2019;39:1435-50.
37. AlAli A, Bushehri A, Park JC, Krema H, Lam WC. Pimasertib and serous retinal detachments. Retin Cases Brief Rep 2016;10:191-6.
38. Avery RA, Trimboli-Heidler C, Kilburn LB. Separation of outer retinal layers secondary to selumetinib. J AAPOS 2016;20:268-71.
39. van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF. Pimasertib-associated ophthalmological adverse events. Acta Ophthalmol 2018;96:712-8.
40. van Dijk EH, van Herpen CM, Marinkovic M, et al. Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (binimetinib) for metastatic cutaneous and uveal melanoma. Ophthalmology 2015;122:1907-16.
41. Watanabe K, Otsu S, Hirashima Y, et al. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2016;77:1157-64.
42. Rueda-Rueda T, Sánchez-Vicente JL, Moruno-Rodríguez A, Molina-Socola FE, Martínez-Borrego AC, López-Herrero F. Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib. Arch Soc Esp Oftalmol 2018;93:458-62.
43. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res 2012;32:1375-7.
44. Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res 2008;32:1022-5.
45. Kitzmann AS, Baratz KH, Mohney BG, et al. Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits. Eye 2008;22:712-4.
46. Fraunfelder FT, Fraunfelder FW. Oral anti-vascular endothelial growth factor drugs and ocular adverse events. J Ocul Pharmacol Ther 2018;34:432-5.
47. Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021;6:803-15.
48. Lam WS, Creaney J, Chen FK, et al. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. Lung Cancer 2020;140:87-92.
49. Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med 2019;36:1075-81.
50. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 2018;38:1063-78.
51. Mantopoulos D, Kendra KL, Letson AD, Cebulla CM. Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 2015;133:965-7.
52. Reddy M, Chen JJ, Kalevar A, Terribilini R, Agarwal A. Immune retinopathy associated with nivolumab administration for metastatic non-small cell lung cancer. Retin Cases Brief Rep 2020;14:120-6.
53. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-80.
